In human epidermal growth factor receptor (HER)-2-positive breast cancer, the standard systemic treatment consists of the combination of paclitaxel-based chemotherapy and an anti-HER-2-antibody treatment using trastuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.